Nucleoside-modified RNA for inducing an immune response against zika virus

Patent metadata

Field	Value
Publication number	US-11241490-B2
Application number	US-201816477258-A
Country	US
Kind code	B2
Filing date	Jan 11, 2018
Priority date	Jan 11, 2017
Publication date	Feb 8, 2022
Grant date	Feb 8, 2022

Abstract

The present invention relates to compositions and methods for inducing an adaptive immune response against Zika virus (ZIKV) in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a ZIKV antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a ZIKV antigen, adjuvant, or a combination thereof.

First claim

What is claimed is:

1. A composition for inducing an immune response against Zika virus (ZIKV) in a subject, the composition comprising at least one isolated nucleoside-modified RNA molecule encoding at least one ZIKV antigen, wherein the at least one ZIKV antigen comprises the amino acid sequence of SEQ ID NO: 2.

2. The composition of claim 1 , wherein the at least one isolated nucleoside-modified RNA molecule comprises at least one modified nucleoside selected from the group consisting of pseudouridine, and 1-methyl-pseudouridine.

3. The composition of claim 1 , wherein the at least one nucleoside-modified RNA comprises the nucleotide sequence of SEQ ID NO: 1.

4. The composition of claim 1 , wherein the composition further comprises an adjuvant.

5. The composition of claim 1 , wherein the at least one nucleoside-modified RNA molecule further encodes at least one adjuvant.

6. The composition of claim 1 , further comprising a lipid nanoparticle (LNP).

7. The composition of claim 6 , wherein the at least one nucleoside-modified RNA is encapsulated within the LNP.

8. The composition of claim 1 , wherein the composition is a vaccine.

9. A method of inducing an adaptive immune response against Zika virus (ZIKV) in a subject comprising administering to the subject an effective amount of the composition of claim 1 .

10. The method of claim 9 , wherein the at least one isolated nucleoside-modified RNA molecule comprises at least one modified nucleoside selected from the group consisting of pseudouridine, and 1-methyl-pseudouridine.

11. The method of claim 9 , wherein the method further comprises administering to the subject an effective amount of an adjuvant.

12. The method of claim 9 , wherein the at least one nucleoside-modified RNA is encapsulated within a LNP.

13. The method of claim 9 , wherein the composition is a vaccine.

14. The method of claim 9 , wherein the composition is administered by a delivery route selected from the group consisting of intradermal, subcutaneous, inhalation, intranasal, and intramuscualar.

15. The method of claim 9 , wherein the method comprises a single administration of the composition.

16. The method of claim 9 , wherein the method comprises a multiple administrations of the composition.

Assignees

• Univ Pennsylvania

Inventors

• Weissman Drew
• Pardi Norbert
• Hogan Michael

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K2039/55511

  Organic adjuvants · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61K39/12 Primary

  Viral antigens · CPC title